Genomictree Inc.
228760
Peringkat dalam Saham
#19189
Genomictree Inc. is a molecular diagnostics firm that harnesses biomarkers to... Genomictree Inc. is a molecular diagnostics firm that harnesses biomarkers to develop and market advanced detection tools for both oncological conditions and various infectious diseases. Its product line includes EarlyTect C, a screening solution for the early identification of colorectal cancer. For lung cancer, it offers EarlyTect L, which targets epigenetic markers in patients with pulmonary nodules, and for bladder cancer, EarlyTect B, designed to detect specific genetic and epigenetic markers in individuals with hematuria. The company also provides a range of companion diagnostics: AccuraTect-KRAS and AccuraTect-BRAF assist in colorectal cancer management, while AccuraTect-EGFR supports lung cancer treatment. In addition, Genomictree supplies AccuraDTect SARS-CoV-2 RT-qPCR kits for infectious disease testing, and offers its technologies to support various diagnostic test providers. Founded in 2000, the company is based in Daejeon, South Korea.
Harga Saham
$6.60
Kapitalisasi Pasar
$162.09M
Perubahan (1 hari)
-0.21%
Perubahan (1 tahun)
-50.08%
Negara
KR
Perdagangan Genomictree Inc. (228760)
Kategori
Healthcare
Riwayat hasil dividen untuk Genomictree Inc. (228760)
Hasil dividen (TTM) dari Genomictree Inc. (simbol saham: 228760) per 2026: 0
Rata-rata hasil dividen selama 5 tahun terakhir: 0.00%
Rata-rata hasil dividen selama 5 tahun terakhir: 0.00%
Riwayat hasil dividen untuk Genomictree Inc. (228760) dari 2026 hingga 2026
Hasil dividen pada akhir setiap tahun (TTM)
| Tahun | Hasil Dividen | Mengubah |
|---|---|---|
| Tidak cukup data untuk tanggal yang disediakan. | ||
Hasil dividen (TTM) untuk perusahaan serupa atau pesaing
| Perusahaan | Hasil Dividen | Negara |
|---|---|---|
| 0.00% |
US
|
|
| 0.00% |
US
|
|
| 2.17% |
AU
|
|
| 0.00% |
CH
|
|
| 0.00% |
NL
|
